Home » Newsletters » BioWorld Science

BioWorld Science

April 4, 2002

View Archived Issues

Development of clinical-stage anticancer drug stopped

Cepharanoline derivative identified with potent and selective activity against HIV-1

Long-term statin therapy for improving outcome following myocardial infarction

Addition of spironolactone to ACE inhibition improves endothelial vasomotor dysfunction in CHF

Another Roche product approved in the E.U.

Antiangiogenic effects demonstrated for CA4P in mouse model of proliferative retinopathy

Two studies highlight efficacy of Elidel in head and neck eczema

Phase IIa trial of TA-CD for cocaine addiction begins

Combination of Androsorb and Estrasorb examined in hormone-deficient women

Positive initial efficacy data from MethyPatch phase III trial in ADHD

Marketing clearance sought for Aldurazyme in Europe

Synaptic enters collaborations with Gruenenthal and Kissei

New dose of Concerta approved by FDA

BTG acquires ophthalmic drug delivery insert technology

Phase II study of Femprox in FSAD completed

Genzyme Molecular Oncology licenses rights to gene associated with colon cancer metastasis

MediGene signs ionizing radiation research agreement with U. of Chicago

AlgoRx completes acquisition of PowderJect's drug business

FluINsure influenza vaccine meets immune response endpoints in phase I trial

Cathepsin S inhibitors in development at Ortho-McNeil

Boehringer Ingelheim presents heterocyclic tyrosine kinase inhibitors

Roche patent covers new inhibitors of lanosterol synthase and their potential uses

Antitumor camptothecin esters reported by California center

Novel peptides inhibit interaction of Abeta with alpha7 nicotinic receptors

Tufts patents tetracycline-based antibacterials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 22, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...